Boosting the Limited Use of Mineralocorticoid Receptor Antagonists Through New Agents for Hyperkalemia.
Τίτλος | Boosting the Limited Use of Mineralocorticoid Receptor Antagonists Through New Agents for Hyperkalemia. |
Publication Type | Journal Article |
Year of Publication | 2018 |
Authors | Athyros, V. G., Sachinidis A. G., Zografou I., Simoulidou E., Piperidou A., Stavropoulos N., & Karagiannis A. |
Journal | Curr Pharm Des |
Volume | 24 |
Issue | 46 |
Pagination | 5542-5547 |
Date Published | 2018 |
ISSN | 1873-4286 |
Abstract | BACKGROUND: Hyperkalemia is an important clinical problem that is associated with significant lifethreatening complications. Several conditions are associated with increased risk for hyperkalemia such as chronic kidney disease, diabetes mellitus, heart failure, and the use of renin-angiotensin-aldosterone system (RAAS) inhibitors. |
DOI | 10.2174/1381612825666190306162339 |
Alternate Journal | Curr. Pharm. Des. |
PubMed ID | 30848186 |